Manual on the proper use of sodium astatide ([(211)At]NaAt) injections in clinical trials for targeted alpha therapy (1st edition).

Manual on the proper use of sodium astatide ([(211)At]NaAt) injections in clinical trials for targeted alpha therapy (1st edition).
复制标题

在靶向α疗法的临床试验中注射astatide钠([[(211)at] Naat)的适当使用手册(第一版)。

DOI:
10.1007/s12149-021-01619-2
复制
发表时间:
2021-07
影响因子:
2.6
通讯作者:
Nakamura Y
Nakamura Y
中科院分区:
医学4区
文献类型:
--
作者:
Watabe T;Hosono M;Kinuya S;Yamada T;Yanagida S;Namba M;Nakamura Y

文献摘要

参考文献

被引文献

相似文献

我们根据日本的辐射安全问题,提出了在临床试验中使用[211 At] Astatide钠(NaAt)进行靶向α治疗的指南。本指南由厚生劳动省支持的一项研究编制,并于2021年2月8日获得日本核医学会批准。该研究表明,接受[211At]NaAt的患者不需要进入放射治疗室,可以进行门诊治疗。患者的辐射暴露在ICRP和IAEA对公众和护理人员建议的安全标准范围内。本指南还包括患者及其家属的注意事项、与[211At]NaAt使用相关的安全管理、教育和培训以及医用放射性污染物的处置。在日本使用[211At]NaAt进行治疗时,应按照本指南进行。虽然该指南在日本适用,但这里所示的辐射防护问题和评估方法在国际上也被认为是有用的。
We present the guideline for use of [211At] sodium astatide (NaAt) for targeted alpha therapy in clinical trials on the basis of radiation safety issues in Japan. This guideline was prepared by a study supported by the Ministry of Health, Labour, and Welfare, and approved by the Japanese Society of Nuclear Medicine on 8th Feb, 2021. The study showed that patients receiving [211At]NaAt do not need to be admitted to a radiotherapy room and outpatient treatment is possible. The radiation exposure from the patient is within the safety standards of the ICRP and IAEA recommendations for the general public and caregivers. Precautions for patients and their families, safety management associated with the use of [211At]NaAt, education and training, and disposal of medical radioactive contaminants are also included in this guideline. Treatment using [211At]NaAt in Japan should be carried out according to this guideline. Although this guideline is applied in Japan, the issues for radiation protection and evaluation methodology shown here are considered internationally useful as well.
DOI: 10.1089/thy.2015.0020
发表时间: 2016-01-01
期刊: THYROID
影响因子: 6.6
作者:
Haugen, Bryan R.;Alexander, Erik K.;Wartofsky, Leonard
通讯作者: Wartofsky, Leonard
DOI: 10.1097/00004032-198004000-00002
发表时间: 1980-01-01
期刊: HEALTH PHYSICS
影响因子: 2.2
作者:
NISHIZAWA, K;OHARA, K;WATANABE, T
通讯作者: WATANABE, T
DOI: 10.1016/j.icrp.2008.08.001
发表时间: 2017-12-01
期刊: Annals of the ICRP
影响因子: --
作者:
Paquet, F.;Bailey, M. R.;Harrison, J. D.
通讯作者: Harrison, J. D.
DOI: 10.1016/j.tranon.2020.100757
发表时间: 2020-04-01
影响因子: 5
作者:
Liu, Yuwei;Watabe, Tadashi;Hatazawa, Jun
通讯作者: Hatazawa, Jun
DOI: 10.2967/jnumed.118.222638
发表时间: 2019-09-01
影响因子: 9.3
作者:
Watabe, Tadashi;Kaneda-Nakashima, Kazuko;Hatazawa, Jun
通讯作者: Hatazawa, Jun